SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Navigating Medtech Reimbursement Strategies for Successful Innovation
Successful medtech reimbursement strategies must be developed in parallel with regulatory approval, because clearance only confirms safety and efficacy while payers separately decide financial coverage. Investors now routinely demand evidence of sustainable payment pathways long before regulatory...
AI Regulatory Research Priorities in Medicine Lifecycle Management
AI Regulatory Research Priorities have crystallised around one central requirement: establishing trustworthy performance of artificial intelligence systems across the entire pharmaceutical development and evaluation pathway. Stakeholders from every corner of the European medicines regulatory netw...
Health Economic Security as a Pillar for Growth in Central and Eastern Europe
Central and Eastern European nations face intensifying demographic pressures, including rapid population aging, shrinking workforces, and heightened security risks that endanger long-term prosperity. In a recent EFPIA statement, health economic security is seen as essential, as targeted healthcar...